About this item:

93 Views | 46 Downloads

Author Notes:

Alper Sonmez, yusufalper.sonmez@sbu.edu.tr

T.D., A.S.—conceived the original idea; A.K., H.G.—performed the patient data collection; T.D., A.K.—analyzed the data and designed the tables and figures; T.D., A.K., A.S.—designed the study; T.D., A.S., M.R., A.A.R.—wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

The authors declare that the current research was conducted independently, in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Rizzo is a full-time Professor of Internal Medicine at University of Palermo, Italy and currently Medical Director, Novo Nordisk Eastern Europe; he has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier. Sonmez has received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies including AstraZeneca, Novo Nordisk, Novartis, Eli Lilly and Sanofi. None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.

Subject:

Research Funding:

This research received no external fundings.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Physical Sciences
  • Biochemistry & Molecular Biology
  • Chemistry, Multidisciplinary
  • Chemistry
  • NAFLD
  • Fetuin-A
  • CVD
  • ALPHA(2)-HEREMANS-SCHMID GLYCOPROTEIN/FETUIN-A
  • IMPAIRED GLUCOSE-TOLERANCE
  • SERUM FETUIN
  • INSULIN-RESISTANCE
  • HEPATIC STEATOSIS
  • CARDIOVASCULAR-DISEASE
  • METABOLIC SYNDROME
  • NONDIABETIC SUBJECTS
  • MORBIDLY OBESE
  • ASSOCIATION

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart

Tools:

Journal Title:

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Volume:

Volume 22, Number 12

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is strongly associated to the features of metabolic syndrome which can progress to cirrhosis, liver failure and hepatocellular carcinoma. How-ever, the most common cause of mortality in people with NAFLD is not liver‐related but stems from atherosclerotic cardiovascular disease (CVD). The prevalence of NAFLD is on the rise, mainly as a consequence of its close association with two major worldwide epidemics, obesity and type 2 diabetes (T2D). The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression and CVD have not been completely elucidated. Human fetuin‐A (alpha‐2‐Heremans Schmid glycoprotein), a glycoprotein produced by the liver and abundantly secreted into the circulation appears to play a role in insulin resistance, metabolic syndrome and inflammation. This review discusses the links between NAFLD and CVD by specifically focusing on fetuin‐A’s function in the pathogenesis of NAFLD and atherosclerotic CVD.

Copyright information:

© 2021 by the authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote